MKP is a tripeptide of methionine, lysine and proline, listed in peptide catalogs and occasionally in neurocognitive product descriptions. As with RKH, the honest report is a short one: the published evidence supporting the claims made for it is minimal.
This guide situates MKP within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
What is actually known
MKP consists of methionine, lysine and proline. Short proline-containing peptides are of general interest in peptide chemistry because proline's ring structure constrains conformation and can confer some resistance to certain peptidases — a structural observation, not a demonstrated biological effect.
Beyond composition, there is no accessible body of published research establishing a defined receptor, mechanism or clinical effect for MKP in humans. There are no clinical trials, and no substantive preclinical literature characterizing what it does.
Why catalog placement means nothing
MKP appears in product listings and formulary tables alongside compounds like Semax and Selank, which have registered use in Russia and an actual clinical literature, however limited.
That adjacency carries an implicit and unearned suggestion: that inclusion in the same list implies comparable standing. It does not. A catalog is an inventory, not an evidence assessment.
This formulary deliberately tags each agent with its regulatory status and gives each an honest guide precisely so that adjacency does not do that work. An agent with FDA approval, an agent with a substantial preclinical literature, and an agent with essentially no research are three different situations that should never be presented as equivalent because they appear in the same table.
How to evaluate a compound like this
The process is the same one set out in our RKH guide and applies to any unfamiliar peptide a patient asks about.
Search by sequence and every synonym, not the marketing name. Determine whether results are human trials, animal work, cell culture, or vendor material. Establish whether a defined mechanism has been characterized rather than merely proposed. Check regulatory status directly rather than relying on a distributor's description.
Where that process returns nothing substantive, the finding is that no one currently knows what the compound does in humans. That is an accurate and useful answer, and it is more respectful of the patient than a confident summary assembled from adjacent research.
MKP is not FDA-approved and is not an established compounding substance. Our peptide formulary carries current status for all 128 agents.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering evaluating peptide claims against the literature, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →